Sugi Predict

Sugi Predict / Compounds / SCHEMBL830740

SCHEMBL830740

SCHEMBL830740

Cc1cccc(C)c1OCC(=O)O

nearest known ligand 0.61

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 5/20 0.60
▸ CD69 Q07108 3/20 0.58
▸ MEN1 O00255 3/20 0.53
▸ SMN1; SMN2 Q16637 2/20 0.53
▸ NPC1 O15118 1/20 0.53
▸ ALDH1A1 P00352 1/20 0.53
▸ RAB9A P51151 1/20 0.53
▸ ALOX15 P16050 2/20 0.52
▸ CASP1 P29466 1/20 0.51
▸ HSD17B10 Q99714 1/20 0.51
▸ LMNA P02545 1/20 0.50
▸ ALPL P05186 1/20 0.49
▸ MAPT P10636 1/20 0.49
▸ NOTUM Q6P988 1/20 0.49
▸ KDM4E B2RXH2 1/20 0.49
▸ FFAR1 O14842 1/20 0.49
▸ L3MBTL1 Q9Y468 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28044483 0.89 KMT2A (0.53) KMT2ACD69MEN1SMN1; SMN2NPC1
SCHEMBL321504 0.89 L3MBTL1 (0.56) KMT2ACD69SMN1; SMN2ALDH1A1CASP1
SCHEMBL1887188 0.87 KMT2A (0.77) KMT2ACD69RAB9AALOX15MAPT
SCHEMBL20509554 0.87 ALDH1A1 (0.60) KMT2ACD69MEN1SMN1; SMN2NPC1
SCHEMBL6743332 0.86 POLB (0.62) KMT2ACD69MEN1SMN1; SMN2ALDH1A1
SCHEMBL14499026 0.85 KMT2A (0.57) KMT2AMEN1SMN1; SMN2NPC1ALDH1A1
SCHEMBL5696285 0.84 ALDH1A1 (0.54) KMT2ACD69SMN1; SMN2ALDH1A1KDM4E
SCHEMBL6089997 0.84 PTGDR2 (0.50) KMT2ACD69MEN1SMN1; SMN2NPC1
SCHEMBL4746689 0.84 PTGDR2 (0.57) KMT2ACD69MEN1SMN1; SMN2NPC1
SCHEMBL836542 0.83 KMT2A (0.56) KMT2AMEN1SMN1; SMN2NPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 198 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115108905-B Method for producing (Z) -trifluoromethaneenol ester by copper-catalyzed regioselective olefination and trifluoromethylation of carboxylic acid 湖南大学 2025-04-08 — — CN claimed
CN-119143772-A TVOC adsorption supermolecule cage and preparation method and application thereof 宁波潮星新材料科技有限公司 2024-12-17 — — CN claimed
CN-111018791-B Novel method for preparing lopinavir 厦门蔚嘉制药有限公司 2021-05-25 — — CN claimed
CN-110903249-B Lopinavir prepared by one-pot method 厦门蔚嘉制药有限公司 2021-05-25 — — CN claimed
CN-112574027-A Production process of 2, 6-dimethylphenoxy acetic acid 盐城迪赛诺制药有限公司 2021-03-30 — — CN claimed
CN-111018791-A Novel method for preparing lopinavir 厦门蔚嘉制药有限公司 2020-04-17 — — CN claimed
CN-110903249-A Lopinavir prepared by one-pot method 厦门蔚嘉制药有限公司 2020-03-24 — — CN claimed
CN-106083564-B A kind of synthesis of 2,6- dimethyl phenoxyacetic acid and purification process 厦门市蔚嘉化学科技有限公司 2019-02-15 — — CN claimed
CN-106083564-A The synthesis of a kind of 2,6 dimethyl phenoxyacetic acids and purification process 厦门市蔚嘉化学科技有限公司 2016-11-09 — — CN claimed
US-7279582-B2 Retroviral protease inhibiting compounds ABBOTT LABORATORIES (US) 2007-10-09 — — US claimed
US-20030100755-A1 Retroviral protease inhibiting compounds ABBVIE INC. 2003-05-29 — — US claimed
EP-0882024-B1 RETROVIRAL PROTEASE INHIBITING COMPOUNDS ABBOTT LAB (US) 2002-02-06 — — EP claimed
US-20020004503-A1 Retroviral protease inhibiting compounds ABBVIE INC. 2002-01-10 — — US claimed
EP-0882024-A1 RETROVIRAL PROTEASE INHIBITING COMPOUNDS Abbott Laboratories (US) 1998-12-09 — — EP claimed
WO-1997021685-A1 RETROVIRAL PROTEASE INHIBITING COMPOUNDS ABBOTT LABORATORIES (US) 1997-06-19 — — WO claimed
CN-119143772-A TVOC adsorption supermolecule cage and preparation method and application thereof 宁波潮星新材料科技有限公司 2024-12-17 — — CN disclosed
US-20220380320-A1 PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING MIDDLE EAST RESPIRATORY SYNDROME GYEONGGIDO BUSINESS & SCIENCE ACCELERATOR (KR) 2022-12-01 — — US disclosed
WO-1989010920-A1 RENIN INHIBITORY PEPTIDES CONTAINING A SUBSTITUTED PHENOXYACETYLE GROUP THE UPJOHN COMPANY (US) 1989-11-16 — — WO disclosed
EP-0104483-A2 Sulfamoyl benzophenon derivatives, process for their preparation, their use, and pharmaceutical compositions based on these compounds HOECHST AKTIENGESELLSCHAFT (DE) 1984-04-04 — — EP disclosed
US-4244731-A APPLYING A CARBOXY DERIVATIVE OF A 2,6-DIMETHYLPHENOXY COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1981-01-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030100755-A1 Retroviral protease inhibiting compounds SERPINB1, PREP, TMPRSS15 KMT2A 3171/4885CD69 2229/4885MEN1 3727/4885
US-20220380320-A1 PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING MIDDLE EAST RESPIRATORY SYNDROME ACE, ACE2, SARS1 KMT2A 2787/4885CD69 4828/4885MEN1 693/4885
US-20020004503-A1 Retroviral protease inhibiting compounds SERPINB1, PREP, TMPRSS15 KMT2A 3171/4885CD69 2229/4885MEN1 3727/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.